Prademagene zamikeracel (pz-cel; formerly EB-101) (Abeona Therapeutics Inc.) is a gene-corrected epidermal sheet under investigation for the treatment recessive dystrophic epidermolysis bullosa.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Vivistim Paired VNS System (MicroTransponder Inc.) for Treatment of Upper Limb Impairment Due to Stroke
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the Vivistim Paired Vagus Nerve Stimulation (VNS) System (MicroTransponder Inc.) for rehabilitation of upper extremity impairment following stroke.
Aortix Percutaneous Mechanical Circulatory Support Device (Procyrion Inc.)
Aortix is an investigational percutaneous mechanical circulatory support device in development for the treatment of chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure with worsening renal function.
Sonpiretigene Isteparvovec (Nanoscope Therapeutics Inc.) for Retinitis Pigmentosa
Sonpiretigene isteparvovec is an investigational gene therapy for retinitis pigmentosa, administered as an intravitreal injection.
Systemic Hyperbaric Oxygen Therapy for Venous Ulcers
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of systemic (chamber) hyperbaric oxygen therapy (HBOT) for the treatment of venous ulcers for improved wound closure and healing.
ADAMTS13, Recombinant-krhn (Adzynma; Takeda Pharmaceutical Co. Ltd.) for Congenital Thrombotic Thrombocytopenic Purpura
Adzynma (Takeda Pharmaceutical Co. Ltd.) is a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (rADAMTS13) indicated for prophylactic or on demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura.
Percutaneous Sacroplasty for Treatment of Sacral Insufficiency Fractures Due to Causes Other Than Malignancy
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of percutaneous sacroplasty for the treatment of sacral insufficiency fractures (SIFs) in adults who primarily have an underlying cause other than malignancy.
Topical Hyperbaric Oxygen Therapy for Venous Ulcers
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of topical (local) hyperbaric oxygen therapy (HBOT) for the treatment of venous ulcers to improve wound healing.
miraDry Microwave Therapy (miraDry Inc.) for Management of Primary Axillary Hyperhidrosis
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the miraDry system (miraDry Inc.) in adult patients with primary axillary hyperhidrosis (PAH) for reduced sweat production and improved quality of life.
Rebonuputemcel Injectable Discogenic Cell Therapy (IDCT; DiscGenics Inc.) for Degenerative Disc Disease
Rebonuputemcel Injectable Discogenic Cell Therapy (IDCT; DiscGenics Inc.) is an allogeneic progenitor cell therapy for the treatment of symptomatic early-to-moderate lumbar degenerative disc disease at a single level from L3 to S1.